Nab-paclitaxel: 120 mg per square meter of body-surface area on days 1, 8, and 15 every 4 weeks
Gemcitabine (1000 mg/m2): (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks
Anti-Diabetics: Metformin, insulin or other anti-diabetic treatments
Active treatment and monitoring: Attend follow-ups at designated endocrinology clinics, with proactive inquiry about hypoglycemic measures and medication implementation.
Study summary
The purpose of this study is to evaluate the efficacy of anti-diabetic treatment on improving the overall survival for metastatic pancreatic cancer patients complicated by diabetes receiving gemcitabine and nab-paclitaxel chemotherapy.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* Ability to understand and the willingness to sign a written informed consent document.
* Age ≥ 18 years and ≤ 80 years.
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
* Histologically or cytologically confirmed metastatic pancreas adenocarcinoma.
* History of diabetes mellitus, or newly diagnosed diabetes meeting the diagnostic criteria of the American Diabetes Association.
* The expected survival ≥ 3 months.
* Able to comply with study visit schedules and other protocol requirements.
Exclusion Criteria:
* • History of other malignancies requiring anti-cancer therapy within 2 years prior to enrollment (except treated Stage I prostate cancer, in situ cervical cancer, in situ breast cancer, etc.);
* Non-primary pancreatic cancer patients;
* Digestive tract inflammation, including biliary tract infection, gastrointestinal infection, pancreatitis, etc.;
* Pregnant or lactating women.
Primary outcome measure(s)
Overall Survival (OS): — 2 months Time from randomization to death from any cause
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.